AGL 5.77 Decreased By ▼ -0.31 (-5.1%)
ANL 9.01 Decreased By ▼ -0.39 (-4.15%)
AVN 78.40 Decreased By ▼ -3.06 (-3.76%)
BOP 5.16 Decreased By ▼ -0.11 (-2.09%)
CNERGY 4.66 Decreased By ▼ -0.24 (-4.9%)
EFERT 80.54 Decreased By ▼ -1.01 (-1.24%)
EPCL 51.97 Decreased By ▼ -2.03 (-3.76%)
FCCL 13.59 Decreased By ▼ -0.81 (-5.63%)
FFL 5.87 Decreased By ▼ -0.18 (-2.98%)
FLYNG 7.09 Decreased By ▼ -0.47 (-6.22%)
FNEL 4.82 Decreased By ▼ -0.18 (-3.6%)
GGGL 8.89 Decreased By ▼ -0.43 (-4.61%)
GGL 15.89 Decreased By ▼ -0.81 (-4.85%)
HUMNL 5.83 Increased By ▲ 0.14 (2.46%)
KEL 2.60 Decreased By ▼ -0.19 (-6.81%)
LOTCHEM 29.94 Decreased By ▼ -0.61 (-2%)
MLCF 25.40 Decreased By ▼ -2.39 (-8.6%)
OGDC 72.23 Decreased By ▼ -1.77 (-2.39%)
PAEL 15.42 Decreased By ▼ -0.77 (-4.76%)
PIBTL 5.03 Decreased By ▼ -0.20 (-3.82%)
PRL 16.37 Decreased By ▼ -0.92 (-5.32%)
SILK 1.09 No Change ▼ 0.00 (0%)
TELE 9.60 Decreased By ▼ -0.44 (-4.38%)
TPL 7.30 Decreased By ▼ -0.40 (-5.19%)
TPLP 19.18 Decreased By ▼ -0.59 (-2.98%)
TREET 21.93 Decreased By ▼ -1.26 (-5.43%)
TRG 144.54 Decreased By ▼ -2.81 (-1.91%)
UNITY 16.60 Decreased By ▼ -0.59 (-3.43%)
WAVES 10.01 Decreased By ▼ -0.37 (-3.56%)
WTL 1.36 Decreased By ▼ -0.10 (-6.85%)
BR100 4,230 Decreased By -100.1 (-2.31%)
BR30 15,822 Decreased By -474.4 (-2.91%)
KSE100 42,071 Decreased By -832.3 (-1.94%)
KSE30 15,504 Decreased By -300.7 (-1.9%)
Follow us

FRANKFURT: Pfizer and BioNTech on Monday said trial results showed their coronavirus vaccine was safe and produced a robust immune response in children aged five to 11, adding that they would seek regulatory approval shortly.

The vaccine would be administered at a lower dosage than for people over 12, they said.

“In participants five to 11 years of age, the vaccine was safe, well tolerated and showed robust neutralising antibody responses,” US giant Pfizer and its German partner said in a joint statement.

They plan to submit their data to regulatory bodies in the European Union, the United States and around the world “as soon as possible”.

The trial results are the first of their kind for children under 12, with a Moderna trial for six-11 year olds still ongoing.

Both the Pfizer and Moderna jabs are already being administered to adolescents over 12 and adults in countries around the globe.

Although children are considered less at risk of severe Covid, there are concerns that the highly contagious Delta variant could lead to more serious cases.

Innoculating children is also seen as key to keeping schools open and helping end the pandemic.

“We are eager to extend the protection afforded by the vaccine to this younger population,” said Pfizer CEO Albert Bourla, noting that “since July, paediatric cases of COVID-19 have risen by about 240 percent in the US”.

Kids in the 5-11 age trial group received a two-dose regimen of 10 microgrammes in the trial, compared with 30 microgrammes for older age groups, the companies said. The shots were given 21 days apart.

The 10 microgramme dose was “carefully selected as the preferred dose for safety, tolerability and immunogenicity” for that age group, the statement said. The side effects were “generally comparable to those observed in participants 16 to 25 years of age”, it added.

Among the most commonly reported side effects in the past have been pain and swelling at the injection site as well as headache, chills and fever.

Israel has already given special authorisation to vaccinate children aged 5-11 who are “at significant risk of serious illness or death” from Covid, using the Pfizer jab at the lower dosage.

Pfizer and BioNTech are also trialling their vaccine on infants aged six months to two years, and on children aged two to five.

The topline results for those trials are expected “as soon as” the fourth quarter of this year, the companies said.

All together, up to 4,500 children aged six months to 11 years have enrolled in the Pfizer-BioNTech trials in the US, Finland, Poland and Spain.

Like its Moderna rival, the Pfizer jab is based on novel mRNA technology that delivers genetic instructions to cells to build the coronavirus spike protein, in order to evoke antibodies when bodies encounter the real virus.

Comments

Comments are closed.

Pfizer says its Covid jab safe for children aged 5-11

IMF, govt begin virtual engagement

Army’s role restricted to constitutional mandate: Bajwa

A democratic Pakistan is in Washington’s own interest: State Dept

Dar willing to allow sugar export?

Terrorism case: ATC extends interim bails of IK, others till Dec 9

Presidential Reference on Reko Diq project: SC to announce short order next week

Tax-exempted areas: FBR sets up checkposts to monitor supplies

Nepra decides to grant QASPPL micro-grid licences

TTP ends ceasefire, orders nationwide attacks

Saudi unveils plan for massive new airport in capital